Edited by
Virginia Arechavala-Gomeza
Alejandro Garanto

2022

The field of RNA therapeutics has rapidly changed over the last few years. Particularly, two mRNA vaccines for SARS-CoV-2 and a customized oligonucleotide for an n-of-1 trial have revolutionized the expectations in the field. Although the use of RNA-based molecules as treatments has been investigated for several decades, this recent surge of applications has seen more and more researchers embarking on the design and assessment of such therapies. The main objective of this book is to provide basic knowledge and a large collection of methods to facilitate the work of these newcomers to the field who want to exploit antisense technology as a therapeutic intervention.